LOGIN
View
reports
PRESS RELEASE
Free
BOSC BOS Better Onli...
BOS Reports Financial Results for the Third Quarter of theYear 2024 BOS Reports Financial Results for the Third Quarter of theYear 2024RISHON LE ZION, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. ("BOS" or the "Company") (NASDAQ: BOSC) a global integrator for supply chain technologies, reported its financial results for the third quarter of the year 2024. Third Quarter 2024 Statements of Operations Highlights: Revenues for the third quarter amounted to $9.83 million, roughly unchanged from the comparable quarter last year.Gross profit margin for the third quarter of 2024 increased to 21.9% compared to 20.9% in the com...
6m 1 EN
PRESS RELEASE
Free
OTLK Outlook Therape...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE E... Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical TrialFinal efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced preliminary topline results of NORS...
10m 1 EN
EUR 238.58
DSY Discovery Limit...
Discovery Limited: Update following rating action Our credit view reflects its strong capitalisation, loss absorbing liabilities and geographic diversification offset by exposure to assets and operating environment in South Africa.
DSY DISCOVERY LIMITED
12m 12m 1 EN
Free Trial
VRNA Verona Pharma A...
Verona Pharma: 3 directors Three Directors at Verona Pharma sold 30,500 shares at between 39.212USD and 40.000USD. The significance rating of the trade was 69/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
VRNA VERONA PHARMA ADS
14m 14m 1 EN
See Also
Relaxations | Optional Tables GSTR-9 | GSTR-9C | FY 2023-24GSTR 2B input tax issue: A new advisory by GSTN on how to fix it for FY 2023-24GSTR 2B input tax issue: A new advisory by GSTN on how to fix it for FY 2023-24Free Trial
SOLB SOLVAY SA
Solvay SA: 1 director A director at Solvay SA bought 1,000 shares at 30.610EUR and the significance rating of the trade was 53/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
14m 14m 1 EN
Free Trial
Encavis AG: 2 directors Two Directors at Encavis AG sold 116,916 shares at 17.500EUR. The significance rating of the trade was 100/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
14m 14m 1 EN
EUR 238.58
105560 KB Financial Gr...
KB Financial Group Inc.: Update to credit analysis Our credit view of KB FG reflects its good asset quality and high portfolio diversification, offset by the increased asset risks in its non-bank and overseas subsidiaries.
105560 KB FINANCIAL GROUP INC.
22m 22m 1 EN
PRESS RELEASE
Free
FOOD Goodfood Market...
Goodfood Reports Fiscal Year and Fourth Quarter 2024 Results with Net ... Goodfood Reports Fiscal Year and Fourth Quarter 2024 Results with Net sales of $153 million and $34 million, Gross Profit of $63 million and $13 million and Adjusted EBITDA¹ of $9 million and $0.5 million, respectivelyRecord annual results in key profitability metrics with gross margin2 of 41.2%, an improvement of 2.4% compared to last fiscal year and adjusted free cash flow1 of $8 million, an improvement of 12 million compared to the same period last yearNet sales of $34 million in the fourth quarter of 2024, with gross profit of $13 million and gross margin2 of 38.1%Net loss of $3 millio...
30m 1 EN
PRESS RELEASE
Free
FOOD Goodfood Market...
Goodfood présente ses résultats de l’exercice et du quatrième trimestr... Goodfood présente ses résultats de l’exercice et du quatrième trimestre 2024 avec des ventes nettes de 153 millions de dollars et 34 millions de dollars, un bénéfice brut de 63 millions de dollars et 13 millions de dollars et un BAIIA ajusté¹ de 9 millions de dollars et 0,5 million de dollars, respectivement.Résultats annuels records dans les mesures clés de la rentabilité avec une marge brute2 de 41,2%, soit une amélioration de 2,4% par rapport à l’exercice précédent et des flux de trésorerie disponibles ajustés1 de 8millions de dollars, soit une amélioration de 12millions de dollars ...
30m 1 EN
PRESS RELEASE
Free
NVA NOVA MINERALS L...
Nova Minerals 2024 Sampling Extends the Gold Anomaly at its Muddy Cree... Nova Minerals 2024 Sampling Extends the Gold Anomaly at its Muddy Creek Prospect by 400m with up to 128.5 g/t Au on its Estelle Gold and Critical Minerals Project, in AlaskaAnchorage, Alaska, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) is pleased to announce additional high-grade gold surface sample assay results from its 2024 exploration season with 6 rock samples grading > 10 g/t Au and 8 soil samples grading > 2 g/t Au, confirming a 400m extension to the high-grade gold zone at its Muddy Creek prospect, within i...
30m 1 EN
PRESS RELEASE
Free
DLY LyondellBasell ...
LyondellBasell to address 2024 Goldman Sachs Industrials and Materials... LyondellBasell to address 2024 Goldman Sachs Industrials and Materials ConferenceHOUSTON and LONDON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB), a leader in the global chemical industry, today announced Michael McMurray, executive vice president and chief financial officer, will participate in a fireside chat at the 2024 Goldman Sachs Industrials and Materials Conference in New York on Wednesday, December 4, 2024, at 8 a.m. EST. Webcast and Presentation Slides AccessA live webcast can be accessed at the time of the event at . A replay of the event will be available a...
30m 1 EN
PRESS RELEASE
Free
HUB HUB CYBER SECUR...
HUB Cyber Security to Discuss First Half 2024 Financial Results and Pr... HUB Cyber Security to Discuss First Half 2024 Financial Results and Provide Corporate Update on December 2, 2024 Conference call will be held on Monday, December 2, 2024, at 9:00 am ETTEL AVIV, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – HUB Cyber Security Ltd. (NASDAQ: HUBC) (“HUB Security”; or the “Company”), a leading provider of cybersecurity solutions and advanced data fabric, has scheduled a conference call with management on Monday, December 2, 2024, at9:00 a.m. ET, to review the first half 2024 results. Conference Call Details Date and Time: Monday, December 2, 20...
30m 1 EN
Research Department
- Research Department
EUR 100.00
IDEAS DE INVERSIÓN: ABRIMOS EL RELATIVO LARGO CAC 40 (AMUNDI 40 CAC) V... IDEAS DE INVERSIÓN: ABRIMOS EL RELATIVO LARGO CAC 40 (AMUNDI 40 CAC) VS CORTO FT MIB (FUTURO SZOA INDEX) Y SEGUROS (AMUNDI STOXX EUROPE BANK) VS BANCOS (FUTURO BULA INDEX) (ANÁLISIS BANCO SABADELL)
31m 31m 1 ES
Free Trial
Premium Snacks Nordic AB: 2 directors A director at Premium Snacks Nordic AB bought 7,720 shares at 17.800SEK and the significance rating of the trade was 34/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
34m 34m 1 EN
Free Trial
00193 Capital Estate ...
Capital Estate Ltd: 1 director A director at Capital Estate Ltd bought 12,491,863 shares at 0.400HKD and the significance rating of the trade was 71/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
00193 CAPITAL ESTATE (P CHIP)
37m 37m 1 EN
Joel Scheiman ... (+4)
- Joel Scheiman
- Julie Boote
- Pelham Smithers
- William Nestuk
PREMIUM
37m 37m 1 EN
Free Trial
Gurit Holding AG: 1 director A director at Gurit Holding AG bought 3,000 shares at 10.932CHF and the significance rating of the trade was 53/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
37m 37m 1 EN
Free Trial
01093 CSPC Pharmaceut...
CSPC Pharmaceutical Group Limited: 1 director A director at CSPC Pharmaceutical Group Limited bought 400,000 shares at 5.080HKD and the significance rating of the trade was 50/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
01093 CSPC PHARMACEUTICAL GROUP LIMITED
38m 38m 1 EN
Free Trial
Bonyf NV: 1 director A director at Bonyf NV sold 1,375 shares at 17.300EUR and the significance rating of the trade was 52/100.Is that information sufficient for you to make an investment decision?This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
39m 39m 1 EN
EUR 171.77
CTY1S CITYCON OYJ
Citycon Treasur...
Moody's Ratings places the ratings of Citycon OYJ on review for downgr... Moody's Ratings (Moody's) has today placed on review for downgrade the Ba1 long-term corporate family rating (CFR), Ba3 junior subordinated rating of Citycon OYJ ("Citycon") and concurrently the backed senior unsecured MTN program rating rated (P)Ba1 and the Ba1 rated backed senior unsecured bonds...
CTY1S CITYCON OYJ
CITYCON TREASURY B.V.
41m 41m 1 EN
Loading... 
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.
ResearchPool Subscriptions
Get the most out of your insights
Why subscribe?
- Access premium insights from a wide range of providers on one convenient platform
- Easily search, browse and choose exactly the research that you want to consume
- Get unbundled research at competitive prices –separate from dealing commissions and other ancillary services
How to subscribe
- Contact us to get started on your subscription
Get in touch
ResearchPool Subscriptions
This report is only available to subscribers
Why subscribe?
- Access premium insights from a wide range of providers on one convenient platform
- Easily search, browse and choose exactly the research that you want to consume
- Get unbundled research at competitive prices –separate from dealing commissions and other ancillary services
How to subscribe
- Contact us to get started on your subscription
Get in touch
